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Abstract
Background: Apo2L/TRAIL has considerable promise for cancer therapy based on the fact that this member of
the tumor necrosis factor family induces apoptosis in the majority of malignant cells, while normal cells are more
resistant. Furthermore, in many cells, when Apo2L/TRAIL is combined with chemotherapy, the effect is
synergistic. The majority of this work has been carried out using cell lines. Therefore, investigation of how patient
tumors respond to Apo2L/TRAIL can validate and/or complement information obtained from cell lines and prove
valuable in the design of future clinical trials.
Methods: We have investigated the Apo2L/TRAIL sensitivity of patient derived pancreatic tumors using a patient
tumor xenograft/ SCID mouse model. Mice bearing engrafted tumors were treated with Apo2L/TRAIL,
gemcitabine or a combination of both therapies.
Results: Patient tumors grown as xenografts exhibited a spectrum of sensitivity to Apo2L/TRAIL. Both Apo2L/
TRAIL sensitive and resistant pancreatic tumors were found, as well as tumors that showed heterogeneity of
response. Changes in apoptotic signaling molecules in a sensitive tumor were analyzed by Western blot following
Apo2L/TRAIL treatment; loss of procaspase 8, Bid and procaspase 3 was observed and correlated with inhibition
of tumor growth. However, in a tumor that was highly resistant to killing by Apo2L/TRAIL, although there was a
partial loss of procaspase 8 and Bid in response to Apo2L/TRAIL treatment, loss of procaspase 3 was negligible.
This resistant tumor also expressed a high level of the anti-apoptotic molecule Bcl-XL that, in comparison, was
not detected in a sensitive tumor. Importantly, in the majority of these tumors, addition of gemcitabine to Apo2L/
TRAIL resulted in a greater anti-tumor effect than either therapy used alone.
Conclusion: These data suggest that in a clinical setting we will see heterogeneity in the response of patients'
tumors to Apo2L/TRAIL, including tumors that are highly sensitive as well as those that are resistant. While much
more work is needed to understand the molecular basis for this heterogeneity, it is very encouraging, that Apo2L/
TRAIL in combination with gemcitabine increased therapeutic efficacy in almost every case and therefore may be
a highly effective strategy for controlling human pancreatic cancer validating and expanding upon what has been
reported for cell lines.
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Introduction
The high mortality rate seen in patients with pancreatic
cancer reflects both the difficulty in early detection and
the lack of effective treatment to augment surgery [1,2] so
that, following diagnosis, the average survival time of the
majority of patients is between 4–5 months [3]. Within
the last few years, the use of the deoxycytodine analog
gemcitabine has been shown to result in improved clini-
cal benefit, slightly longer mean survival time and has
become the first line chemotherapy for pancreatic adeno-
carcinoma [4,5]. However, since the five-year survival rate
has remained at 4%, many new approaches to the treat-
ment of pancreatic adenocarcinoma are being investi-
gated [5,6]. Several of these approaches focus on
combination therapies in which gemicitabine is com-
bined with a second cytotoxic agent (e.g. auristatin-PE,
[7]), or a targeted biological therapy (e.g.; the anti-EGFR
antibody C225, [8,9]; OSI-774, Tarceva, [10]).
In 1995, a new member of the tumor necrosis factor
(TNF) family was independently identified by two differ-
ent groups and named TRAIL (Tumor Necrosis Factor
Related Apoptosis Inducing Ligand, [11]) and Apo2L
(based on its homology to Fas/Apo1L [12]). This mole-
cule induces apoptosis in a large number of human tumor
cell lines, both in vitro and in vivo, while normal cells are
not susceptible [11-15]. This is in contrast to other mem-
bers of this family of ligands (i.e. TNF and FasL), which
have marked toxicity when administered systemically (for
further discussion see recent reviews by [16-18]). An
important natural role for Apo2L/TRAIL in the immuno-
surveillance of tumors has been proposed based on its
expression on several immune cells, including activated
NK and T cells (see [19]for discussion). This natural role
of Apo2L/TRAIL in anti-tumor activity provides further
rationale for attempting to develop Apo2L/TRAIL as a
therapeutic molecule. The original studies with Apo2L
showed that it could act synergistically with the chemo-
therapeutic agents 5-FU and CPT-11 in animal studies
using a colon tumor cell line [14,20]. There have since
been numerous studies expanding these observations
using a large number of cell lines of different tumor types
with a variety of chemotherapies, both in vitro and in vivo.
Among the types of solid tumors that have been studied
are breast [21], lung [22], prostate [23], mesothelioma,
[24], renal [25], ovarian [26], bladder [27], glioma [28]
and pancreas [29]. However, there is a concern that these
results might not be predictive of the response of actual
patients' tumors. Therefore, an investigation of how
patient tumors respond to Apo2L/TRAIL could validate
and/or complement information obtained from cell lines
and prove valuable in the design of future clinical trials.
Our group has previously investigated the efficacy of
Apo2L/TRAIL and CPT-11 combination therapy on
patient-derived  colon tumors [30] using a SCID mouse
xenograft model that our lab has developed [31-34]. The
value of this model is that it enables evaluation of actual
patient tumors that retain the heterogeneity and histolog-
ical architecture of the original tumor. TRAIL exerted a sig-
nificant anti-tumor effect on three different patient colon
tumors grown as xenografts and this effect was signifi-
cantly augmented by the addition of CPT-11 or 5-FU [30].
However, use of this model has also revealed the existence
of patient-derived colon tumors which are resistant to
Apo2L/TRAIL alone but are sensitive to the combination
of Apo2L/TRAIL and CPT-11 (Kenji, manuscript in prepa-
ration) This suggested the possibility that a differential
response to Apo2L/TRAIL may occur between patients
and that additional research is critical for 1) appreciating
the degree to which variability occurs between tumors, 2)
developing strategies for using Apo2L/TRAIL in combina-
tion therapies and 3) determining methods for predicting
ahead of time which patients will benefit from Apo2L/
TRAIL.
It has previously been reported that pancreatic cell lines
exhibit varying degrees of sensitivity to Apo2L/TRAIL and
that some of these lines are extremely resistant
[35,29,36,37]. It has also been reported that resistant cells
can be sensitized to Apo2L/TRAIL (e.g. [29,38]). However,
although the combination of Apo2L/TRAIL and gemcitab-
ine  in vitro has been investigated using pancreatic cell
lines, there have been conflicting reports on whether this
combination does [39] or does not [40] have a synergistic
cytotoxic effect.
In this paper, we describe our experience in evaluating five
different patient pancreatic tumors grown in SCID mice to
Apo2L/TRAIL. The recombinant form of human Apo2L/
TRAIL used shows low activity against the murine TRAIL
receptor and therefore this model may not reveal any
potential toxicities of Apo2L/TRAIL, however it does pro-
vide a relevant model for evaluating the sensitivity of
patient tumors. Our data support the idea that some
patients' tumors may exhibit significant sensitivity while
others may be resistant. Still other patients' tumors may
be heterogeneous and exhibit regions of both sensitivity
and resistance. However, the combination of Apo2L/
TRAIL and gemcitabine can enhance the anti-tumor effect
against Apo2L/TRAIL sensitive tumors and, importantly,
can overcome resistance to either single agent, and result
in suppression of resistant tumors. Thus, these findings
predict that patients' tumors will exhibit both sensitivity
and resistance to Apo2L/TRAIL treatment and that it may
be possible to develop approaches for overcoming this
resistance by combining Apo2L/TRAIL and
chemotherapy.Journal of Translational Medicine 2005, 3:22 http://www.translational-medicine.com/content/3/1/22
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The histological features of patient pancreatic adenocarcinomas (left hand panels: A, C, E, G) are maintained when these  tumors are grown as xenografts (right hand panels: B, D, F, H) in SCID mice Figure 1
The histological features of patient pancreatic adenocarcinomas (left hand panels: A, C, E, G) are maintained when these 
tumors are grown as xenografts (right hand panels: B, D, F, H) in SCID mice. The well differentiated glands (arrows) contain-
ing secretory material (double arrows) which are seen in surgical specimens, proliferate in xenografts of the same tumors. 
(Tumor #1: A, B; Tumor #2: C, D; Tumor #3: E, F; Tumor #4: G, H). Original magnification, ×10.Journal of Translational Medicine 2005, 3:22 http://www.translational-medicine.com/content/3/1/22
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Materials and methods
Patient pancreatic tumor-SCID mouse model
Our use of the SCID mouse-patient tumor xenograft
model has been previously described
([31,33,41,32,34,30]). For these studies, surgical speci-
mens of patients' pancreatic tumors were received shortly
after resection through the Tissue Procurement Facility
(TP) of RPCI and cut into 2 mm × 2 mm pieces in tissue
culture medium (RPMI 1640) under sterile conditions.
SCID mice were then anesthetized by intraperitoneal
injection of 0.4–0.5 ml Avertin (2.5 g 2,2,2-tribromoeth-
anol dissolved in 5 ml 2-methyl-butanol/200 ml ddH2O)
and individual tumor pieces were implanted subcutane-
ously in the abdominal wall of three mice (1st passage)
and monitored for growth. The mice used in all experi-
ments were 7–8 weeks old CB17 SCID mice with an aver-
age weight of 18–20 g. They were kept in sterile cages (4–
5 mice per cage) and fed with autoclaved chow and water.
Mice were maintained in air-conditioned and light con-
trolled rooms (12 hr cycles). All procedures, injections
and tumor measurements were carried out under a lami-
nar flow hood using aseptic precautions. Tumor speci-
mens that grew to a size of 1 cm (8–12 weeks) were
retrieved and subsequently passaged into recipient mice
(2nd passage) and were considered to have successfully
engrafted when these tumors grew. Pathological diagnosis
of patient specimens and evaluation of engrafted/ pas-
saged tumors was performed in collaboration with a
member of the Pathology Department at RPCI.
Experimental design
Five different pancreatic adenocarcinomas that success-
fully engrafted into SCID mice were selected for passage
into groups of experimental mice. Tumors reached 4–5
mm in diameter in approximately 4–6 weeks and the mice
were divided into experimental groups of similar tumor
sizes. These tumors are referred to as Tumor #1
(TP#10791), Tumor #2 (TP#10978), Tumor #3
(TP#11424), Tumor #4 (TP#12424), and Tumor #5
(TP#11727).
Apo2L/TRAIL
Apo2L/TRAIL used in this investigation was prepared by
Genentech, Inc. as described previously [14] and provided
as a gift by Genentech and Amgen. A cycle of treatment
with Apo2L/TRAIL consisted of daily intraperitoneal
injection of 500 µg Apo2L/TRAIL /200 ul saline for 14
days. Mice received 2 such cycles separated by a 7–10 day
rest period. Control mice received sterile saline. Tumor
volume was calculated with the formula V= LD × (SD)2 /
2, where V is the tumor volume, LD is the longest tumor
diameter and SD is the shortest tumor diameter. Data was
graphed and the Students unpaired t-test was calculated
using SigmaPlot. At various time points during and at the
termination of an experiment, mice were sacrificed and
pieces of tumor were fixed in formalin, snap-frozen in cry-
ovials in liquid nitrogen, or both, for subsequent analysis.
Sections of all tumor samples were processed for light
microscopy by standard methods.
Apo2L/TRAIL significantly inhibited the growth of pancreatic adenocarcinoma #1 Figure 2
Apo2L/TRAIL significantly inhibited the growth of pancreatic adenocarcinoma #1. Mice bearing patient tumor xenografts were 
treated with Apo2L/TRAIL and the tumor volumes on the final day of treatment (day 35) were compared (7 mice/group, the 
mean is indicated by the horizontal line; p = 0.004). B, C: Comparison of the histology of the median tumors. B. In the periph-
ery of an untreated tumor, there are numerous large glands (arrow) containing secretory product. C. The treated tumor has 
fewer glands (arrow) and a higher proportion of connective tissue. There are also large pools of residual secretory product (S) 
that are not surrounded by epithelial cells.
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Chemotherapy
Gemcitabine (Gemzar, Eli Lilly obtained from McKesson,
Buffalo, NY) was administered by intraperitoneal injec-
tion daily 5 days/wk in two two-week cycles with a rest
interval of one week at doses between 1.0 – 2.5 mg/kg as
indicated. Therefore mice received 7.5–13.5 mg/kg
weekly, which is less than that routinely administered
clinically to patients (25 mg/kg/week).
TUNEL assay
Apoptosis was evaluated by terminal deoxynucleotidyl
transferase-mediated dUTP-nick end-labeling (TUNEL)
staining (ApopTag, Intergen, Corp) according to the man-
ufacturers instructions.
Western blotting
Cell and tissue lysates (lysis buffer containing 20 mM Tris
pH 7.5, 120 mM NaCl, 100 mM NaF, 0.5% Nonionic P40,
200  µM Na3VO4, 50 mM β -Glycerophosphate, 10 mM
NaPPi, 4 mM PMSF, 10 µg/ml Leupeptine, 2 mM Benza-
midine, 10 µg/ml Aprotinin) were separated by SDS-
PAGE and transferred to nitrocellulose membrane. Blots
were immunostained by standard techniques: non-spe-
cific binding was blocked and membranes were incubated
overnight at 4°C with primary antibody. Antibodies used
were anti-caspase 8 (Oncogene # AM46), anti-Bcl-XL, (Cell
Signaling #2762), anti-Bid (Cell Signaling #2002), anti-
human mitochondria (Chemicon #Mab 1273; recognizes
a 65 kd epitope on the membrane of intact human mito-
chondria) and anti-Caspase 3 (Imgenex IMG-144). This
was followed by washing, incubation with peroxidase-
conjugated secondary antibody and visualization of the
bands by enhanced chemoluminescence (ECL) and expo-
sure of the blots to Kodak BioMax film. Anti β -actin was
used as a loading control.
Immunohistochemistry
Immunohistochemical evaluation of p53 (mouse mono-
clonal antibody DO-7, Novocasta) was performed on sec-
tions of formalin fixed, paraffin embedded tumors.
Growth of Tumor #2 is also significantly inhibited during treatment with Apo2L/TRAIL Figure 3
Growth of Tumor #2 is also significantly inhibited during treatment with Apo2L/TRAIL. A. Control; B. Apo2L/TRAIL treated. 
(4 mice/group; day 35, p = 0.016). Following cessation of treatment (arrows), growth of treated tumors progressed at a rate 
similar to that of the untreated tumors.
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Antigen retrieval was accomplished with DAKO Target
Retrieval Solution using a Black and Decker steamer for 20
minutes followed by a 20 minute cooling period.
Results and discussion
Patient pancreatic adenocarcinomas engrafted into SCID 
mice maintain the histological features of the original 
tumor
In order to evaluate the sensitivity of patient pancreatic
tumors to novel therapeutic agents, we have developed a
patient tumor/SCID mouse xenograft model in which
specimens of pancreatic adenocarcinomas obtained
directly from surgeries performed at Roswell Park Cancer
Institute are established as xenografts in SCID mice. Suc-
cessful engraftment has been obtained in 33% of pancre-
atic tumors (18 of 53 tumors implanted over a six year
period), including both adenocarcinomas and neuroen-
docrine tumors. The tumors used in this study were
selected randomly from available patient tumor
xenografts. Histological evaluation of these tumors dem-
onstrated that engrafted tumors maintained a remarkable
degree of similarity, in terms of the histological features
seen, to the original tumors. The malignant cells of the
xenografts formed glands resembling those in the
patients' tumors and secretory material was often seen in
the lumen of these glands (Figure 1). As in the patient
tumors, these glands are separated and surrounded by
stromal tissue.
The growth of patient-derived pancreatic 
adenocarcinomas can be inhibited by Apo2L/TRAIL
In our initial experiment, we treated mice engrafted with
Tumor #1 with two cycles of Apo2L/TRAIL following a 5
week schedule (500 µg/mouse- daily for 2 weeks, 1 week
no treatment, daily for 2 weeks). At the end of the five
weeks, the sizes of the tumors in the treated group were
significantly smaller that those in the control group (Fig-
ure 2A). Histological analysis of the median tumor in each
group showed that there were areas of substantial necrosis
in the interior of these tumors. However, the periphery of
an untreated tumor consisted of numerous glands of fairly
uniform size containing copious amounts of secretory
material (Figure 2B). In contrast, in the smaller, treated
tumor (Figure 2C), the majority of the remaining glands
were smaller, further apart and contained less secretory
material. Also, in comparison to the untreated tumor, the
treated tumor consisted of proportionately more connec-
tive tissue. Interestingly, in the periphery of the treated
tumor, there were pools of secretory material that were
not contained in glands, suggesting that the epithelial
cells that formed these glands had been lost (Figure 2C).
However, even though there was a marked anti-tumor
effect of Apo2L/TRAIL on this tumor, the tumor was not
totally eradicated and areas of viable tumor cells
remained. Similar results were obtained with a second
patient tumor (Tumor #2; Figure 3). The growth of this
tumor was also significantly inhibited during the 35 day
schedule of treatment with Apo2L/TRAIL. However, we
observed that tumor growth resumed after cessation of
Evaluation of the response of Tumor #2 to increasing doses of gemcitabine Figure 4
Evaluation of the response of Tumor #2 to increasing doses of gemcitabine. A. Control; B. Tumors in mice treated with 1.0 
mg/kg gemcitabine grow at a rate comparable to that of untreated tumors; C. Tumors in mice treated with 1.5 mg/kg gemicit-
abine show growth inhibition to varying degrees (p = .045); D. Tumors in mice treated with 2.5 mg/kg gemcitabine alone show 
uniform suppression (p < .001).
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treatment and these tumors grew at a rate similar to that
of the untreated controls. Therefore, although Apo2L/
TRAIL can significantly suppress tumor growth, it may not
prove to be totally efficacious as a single agent and it is
important to develop strategies to use it in combination
with other therapeutic agents.
Combination therapy with Apo2L/TRAIL and gemcitabine 
resulted in enhanced inhibition of tumor growth over that 
of either single agent alone
We next carried out a series of experiments to determine
whether the efficacy of Apo2L/TRAIL against patient
derived pancreatic adenocarcinomas could be enhanced
by using it in combination with gemicitabine. The results
of an experiment using Tumor #2, demonstrated a dose
dependent response of this tumor to gemcitabine and
based on the fact that 1.5 mg/kg moderately, but incom-
pletely, suppressed tumor growth (Figure 4), we chose this
dose for future experiments in order to best observe any
benefit of combination therapy. Subsequently, tumor
bearing mice were treated with 500 µg of Apo2L/TRAIL
alone (for a 35 day schedule as above), 1.5 mg/kg of gem-
citabine alone (5x/week) or the two agents in combina-
tion. The responses of four different patient tumors to
combination therapy were investigated and the results
indicate interesting diversity in the responses of these
tumors.
One tumor, Tumor #3 was sensitive to both Apo2L/TRAIL
and gemcitabine alone and underwent significant growth
inhibition in response to either of these agents. Although
growth suppression by combination treatment was not
statistically different from the effects of either single treat-
ment alone, the anti-tumor effect appears to be enhanced
and these tumors underwent complete regression (Figure
5, A–D). This tumor was consistently sensitive to Apo2L/
TRAIL in several passages (data not shown).
The effect of Apo2L/TRAIL in combination with gemcitabine on an Apo2L/TRAIL sensitive and resistant pancreatic  adenocarcinoma Figure 5
The effect of Apo2L/TRAIL in combination with gemcitabine on an Apo2L/TRAIL sensitive and resistant pancreatic adenocarci-
noma. A-D. Tumor #3; E-H. Tumor #4. Groups of tumor bearing mice were treated with: A&E- Controls, B&F- Apo2L/
TRAIL alone, C&G- gemcitabine alone, D&H- Apo2L/TRAIL and gemcitabine in combination. Tumor #3 is sensitive to Apo2L/
TRAIL alone (B; p = 0.006) while Tumor #4 is resistant to Apo2L/TRAIL (F). This differential sensitivity is also seen in the 
response to gemcitabine alone (C, p = 0.02, and G). The efficacy of Apo2L/TRAIL in combination with gemcitabine appears to 
be enhanced in Tumor #3 (D) and is significantly greater than either treatment alone in Tumor #4 (H; p = 0.008).
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In contrast to Tumor #3, Tumor #4 exhibited resistance to
both Apo2L/TRAIL and gemcitabine when administered
as single agents. However, the use of these two agents in
combination was able to overcome this resistance and
significant tumor growth inhibition was achieved (Fig 5,
E–H ).
Tumor #2 showed variability in sensitivity to Apo2L/
TRAIL. Although, when originally evaluated, Tumor #2
had demonstrated sensitivity to Apo2L/TRAIL alone, in a
subsequent experiment, growth was not significantly sup-
pressed by either Apo2L/TRAIL or gemcitabine alone (Fig-
ure 6, A–D). In this case, however, tumor growth was
significantly inhibited by treatment with the agents in
combination. During this experiment, one representative
tumor was removed from each group on day 7 and pre-
pared for histology (Figure 7, A–D). The normal histolog-
ical appearance of this adenocarcinoma is shown in a
control; this tumor consisted of elaborate glands contain-
ing copious secretory material and a moderate amount of
stroma (Figure 7A). In comparison, both the Apo2L/
TRAIL (Figure 7B) and gemcitabine (Figure 7C) treated
tumors demonstrated evident histological changes with
fewer, smaller glands. In marked contrast to the tumors
treated with single agents alone, the tumor treated with
the combination therapy consisted almost entirely of
fibrotic connective tissue and contained only isolated foci
of viable tumor cells (Figure 7D). Staining of these tumors
with the TUNEL assay showed very few apoptotic cells in
the untreated or gemicitabine alone treated tumors (Fig-
ure 7, E and 7 G). However, large numbers of apoptotic
cells are present in both the tumors treated with Apo2L/
TRAIL alone and Apo2L/TRAIL in combination with gem-
citabine (Figure 7, F and 7 H). This experiment with
Tumor #2 was repeated and although there was heteroge-
neity in the growth of tumors within each treatment
group, the results were similar in that significant tumor
growth inhibition was achieved by combination therapy
(data not shown). The evaluation of Tumor #5 (Figure 6,
E–H) yielded similar results in that growth of the tumors
The anti-tumor effect of Apo2L/TRAIL and gemcitabine in combination is greater than that of either single agent alone Figure 6
The anti-tumor effect of Apo2L/TRAIL and gemcitabine in combination is greater than that of either single agent alone. Mice 
were engrafted with two different patient tumors: A-D, Tumor #2; E-H, Tumor #5. Treatment: A, E. Control; B, F. Apo2L/
TRAIL; C, G. gemcitabine; D, H. combination therapy. Although tumors showed variable degrees of sensitivity to either 
Apo2L/TRAIL or gemcitabine alone, the combination treatment resulted in significant inhibition of tumor growth (D, p = 0.035; 
H, p = 0.05).
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in the untreated group was variable and tumor growth was
not significantly suppressed by either Apo2L/TRAIL or
gemcitabine. However, combination therapy was able to
significantly suppress growth of Tumor #5 (Figure 6H).
At this time, the basis for the cooperation between Apo2L/
TRAIL and gemcitabine is not known. It is likely that
knowledge about the expression of molecules such as p53
in these tumors will be important in understanding fac-
tors which affect sensitivity to chemotherapy. Although
we have not sequenced p53 for mutations, we have evalu-
ated p53 expression by immunohistochemistry in Tumors
#2, 3, 4 and 5. Whereas p53 overexpression was not
detected in Tumors #2, 3 and 4, heterogeneous overex-
pression was detected in Tumor #5 (data not shown). This
suggests that the responses of these tumors to combina-
tion therapy may be independent of p53 status. It has
been demonstrated that the response of tumors to gemcit-
abine can occur in a p53 independent manner in [42].
Future studies investigating the mechanism(s) of cooper-
ation between Apo2L/TRAIL and gemicitabine will
include analyses of the status of critical molecules such as
p53.
Thus, these tumors demonstrated a heterogeneous range
of responses to Apo2L/TRAIL. Tumor #3 is significantly
sensitive to killing with Apo2L/TRAIL alone and this was
consistently seen in subsequent experiments. Interest-
ingly, Tumors #4 and 5 were resistant to Apo2L/TRAIL
alone in the passage that was evaluated. It is informative
that with Tumor #2, which was evaluated in several exper-
iments, the response varied in different passages.
Although the basis for this variability is unknown, it
seems likely that this is the result of an inherent heteroge-
neity in the original tumor. Alternatively, this may indi-
cate the response of this tumor to different factors in the
tumor microenvironment. Interestingly, even when
Tumor #2 was not inhibited by Apo2L/TRAIL alone, an
increased amount of apoptosis was detected within the
tumor early in the treatment. Although this variability is
problematic, it is likely reflective of the situation that can
be expected in the clinic and therefore, it is especially
encouraging that combination therapy with gemcitabine
shows such potential for complementing and enhancing
the anti-tumor effect of Apo2L/TRAIL in the majority of
these tumors.
Investigation of the basis for the difference in sensitivity to 
Apo2L/TRAIL
To further investigate the response of a sensitive and
resistant tumor to Apo2L/TRAIL, we analyzed tumors
from the experiments with Tumors #3 and #4 shown in
The effect of Apo2L/TRAIL and gemcitabine alone and in combination (Tumor #2, day 5 of treatment) Figure 7
The effect of Apo2L/TRAIL and gemcitabine alone and in combination (Tumor #2, day 5 of treatment). A. Many large glands 
are apparent in an untreated tumor. B, C. Tumors treated with Apo2L/TRAIL (B) or gemicitabine (C) contain fewer, smaller 
glands. D. Tumors treated with a combination of Apo2L/TRAIL and gemcitabine consist mainly of fibrotic tissue with foci of 
residual tumor cells (D, arrow). E-H. TUNEL assay. Few apoptotic cells are apparent in either the untreated (E) or gemcitab-
ine treated (G) treated tumors. The Apo2L/TRAIL (F) and combination treated (H) tumors contain numerous cells undergo-
ing apoptosis.Journal of Translational Medicine 2005, 3:22 http://www.translational-medicine.com/content/3/1/22
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Figure 5. Two mice were removed from the control and
Apo2L/TRAIL treated groups on the second day of treat-
ment (6 hours following treatment) and these tumors
analyzed by Western Blot (Figure 8). We observed a dis-
tinct difference in the levels of several critical molecules in
the apoptotic pathways in response to Apo2L/TRAIL. In
Tumor #3 (Figure 8A), which is sensitive to Apo2L/TRAIL,
greatly reduced levels of procaspase 8 and Bid are detected
in the tumors following Apo2L/TRAIL treatment. Reduced
levels of intact human mitochondria are also observed
and there is a clear reduction in detectable procaspase 3.
Samples of Tumor #4 were similarly examined. As can be
seen in Figure 8B, tumors treated with Apo2L/TRAIL have
only slightly reduced amounts of procaspase 8 and Bid
and the levels of intact mitochondria and procaspase 3 are
comparable to those seen in untreated tumors. These
results suggest that Tumor #3 undergoes activation of pro-
caspase 8 and 3 in response to Apo2L/TRAIL and that sig-
naling through Bid cleavage results in recruitment of the
mitochondrial pathway and subsequently, apoptosis. On
the other hand there is only partial activation of procas-
pase 8 in the resistant Tumor #4 suggesting that there is a
defect upstream of caspase 8 activation which results in
failure to adequately activate caspase 8 and thereby initi-
ate apoptotic signaling. One possible explanation for this
reduced activation of caspase 8 could be a defect in
Apo2L/TRAIL receptor expression on the surface of these
cells and this remains to be determined.
It has been previously reported that resistance of estab-
lished pancreatic cell lines to Apo2L/TRAIL and chemo-
therapy is in part associated with levels of the anti-
apoptotic molecule Bcl-XL  [35,43]. Therefore the
expression of Bcl-XL, a molecule that can block the loss of
mitochondrial membrane potential, was investigated in
these tumors. Bcl-XL expression was found to be high in
several samples of the resistant Tumor #4, compared to
the sensitive Tumor #3 in which Bcl-XL was undetectable
in several passages (Figure 9). This differential expression
of the anti-apoptotic molecule Bcl-XL in a tumor that is
resistant to Apo2L/TRAIL is consistent with the idea that
in Tumor #4, in which only little caspase 8 activation
occurs, Bcl-XL may play a role in the resistance by inhibit-
ing activation of the intrinsic apoptotic pathway by the
low levels of cleaved Bid.
Trauzold [37] characterized five pancreatic cell lines with
regard to Apo2L/TRAIL sensitivity and concluded that
although Bcl-XLwas differentially expressed in sensitive
(Capan1, Colo357) vs. resistant (PancTul, Panc89,
Panc1) cells and made a significant contribution to the
observed resistance to Apo2L/TRAIL, it is not the only fac-
tor. These authors concluded that resistance arose from
the combined effects of the downregulation of pro-apop-
totic molecules (FADD, Bid) and the concurrent upregula-
tion of anti-apoptotic molecules (Bcl-XL, FLIP or IAP).
Their experiments support the idea that there is a balance
of several pro- and anti-apoptotic factors in pancreatic
cells that ultimately determines the efficacy of the apop-
totic signal. Recently, Bai et al. have found that knock-
down of Bcl-XL in pancreatic cells that predominantly
The effect of Apo2L/TRAIL on levels of procaspase 8, Bid, a  marker of intact mitochondria, and procaspase 3 in Tumor  #3 (Apo2L/TRAIL sensitive) and Tumor #4 (Apo2L/TRAIL  resistant) Figure 8
The effect of Apo2L/TRAIL on levels of procaspase 8, Bid, a 
marker of intact mitochondria, and procaspase 3 in Tumor 
#3 (Apo2L/TRAIL sensitive) and Tumor #4 (Apo2L/TRAIL 
resistant). Two tumors were removed from each group 
shown in Figure 5 on day 2 of treatment. The lanes are: (+) - 
positive control for each antibody; C- two tumors from the 
control group; T- two tumors from the Apo2L/TRAIL 
treated group; A. The Apo2L/TRAIL sensitive Tumor #3. By 
the second day of treatment with Apo2L/TRAIL, the levels of 
procaspase 8, Bid, the mitochondrial marker and procaspase 
3 (outlined) in these tumors are greatly reduced. B. The 
Apo2L/TRAIL resistant Tumor #4. In the tumor that was 
resistant to Apo2L/TRAIL treatment, although there is a 
slightly diminished amount of procaspase 8 and Bid present in 
these tumors following 2 days of treatment with Apo2L/
TRAIL, the levels of the mitochondrial marker and procas-
pase 3 (outlined) remain comparable to the controls. (In A 
and B a representative actin loading control is shown for 
each tumor).
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overexpress it, results in increased sensitivity of these cells
to TRAIL in combination with other anti-tumor drugs
[44]. The possible role of Bcl-XL and other critical mole-
cules, particularly those upstream of caspase 8, in resist-
ance of patient pancreatic tumors to Apo2L/TRAIL needs
to be more fully investigated. Additionally, the mecha-
nism(s) of the interaction between Apo2L/TRAIL and
gemcitabine needs to be determined.
Conclusion
Although much more work needs to be done, especially in
evaluating a larger number of patients' tumors, these stud-
ies are important because they investigate for the first time
the response of patient pancreatic tumors, grown as
xenografts in SCID mice, to Apo2L/TRAIL. The results
confirm previous work done with cell lines and support
the idea that both the sensitivity and resistance to killing
by Apo2L/TRAIL that has been observed in cell lines will
be seen in patient tumors. Furthermore, these patients'
tumors show heterogeneity of responsiveness both
between tumors and within the same tumor that may be
predictive of variability in a clinical setting. Importantly,
it is encouraging that the combination of Apo2L/TRAIL
with gemicitabine is able to enhance the antitumor effi-
cacy and results in significant suppression of tumors that
exhibit resistance to either one or both of these therapeu-
tics. One potential benefit that remains to be explored is
whether the enhanced efficacy achieved with combina-
tion therapy will allow lower doses of chemotherapy and/
or Apo2L/TRAIL to be used, thus reducing the possibilities
of toxicity and acquired resistance. The results of this
study strongly support the further development of Apo2L/
TRAIL as a therapeutic agent for the treatment of pancre-
atic adenocarcinoma.
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